PNC and BAC TARP WarrantsA friend of mine shares his True Wealth Systems newsletter (Stansberry). Without divulging the entire content (the subject of a previous post from Travis with which I agree), they basically recommend PNC and BAC TARP warrants. I know Travis previously recommended PNC’s. I notice that the newsletter bases its recommendation on a P/B value ranging […]
(e) Resumption of clinical investigations. An investigation may only resume after FDA (usually the Division Director, or the Director's designee, with responsibility for review of the IND) has notified the sponsor that the investigation may proceed. Resump[...]
$KITE - http://www.businesswire.com/news/home/20160329006379/en/Children%E2%80%99s-Hospital-Los-Angeles-Initiate-Clinical-Trial[...]
$GILD - FYI, upcoming CEO's comment on potential areas of acquisitions: http://www.bloomberg.com/news/articles/2016-02-02/gilead-says-this-year-s-sales-will-fall-short-of-estimates?utm_medium=nl&utm_source=internal&mkt_tok=3RkMMJWWfF9wsRoku6nNdu%2FhmjTEU5z[...]
Re: $ACEL Thanks Dr. KSS and I am indeed well. My potential "attraction" to this IPO was, in part, due to the named underwriters as well as the fact that the company had $1.9B in revenues over the last 12 months. We'll watch and learn.[...]
Re: IPO Just ran across this press release and was wondering if our medical experts could chime in: Acelity Holdings, a global medical technology company developing advanced wound care and regenerative medicine, filed on Wednesday with the SEC to raise u[...]
Re: IPO RegenxBIO filed for an IPO. It just finished a series D round. http://www.bizjournals.com/baltimore/news/2015/08/17/venture-backed-rockville-biotech-firm-files-for.html?ana=yahoo According to the article: RegenxBio's gene therapy technology int[...]
Re: $LLY Probably because "There are some big caveats to report, as the study failed to track significant results for two other key measures: A Mini Mental State Examination (MMSE) and the Clinical Dementia Rating scale Sum of Boxes (CDR-SB)."[...]
$PARN Everyone, my sincere apologies. I DID NOT catch that the news was released on June 18th. I thought it was July 18th. Joe: thank you for correcting me and indeed the question is why hasn't it done better. The analysis of the candles stand though. How[...]
Re: $PARN - Indeed it has been in a general downtrend. Thursday's hammer candle followed by Friday by a solid white candle may indicate a trend reversal. There is a minimal volume. Whether Saturday's news is enough to lift this (significantly) higher is [...]
Re: $PARN On a subject other than $ARTH for a change, for those of you in $PARN or thinking of getting in, company announces positive results of its trial; secures a non-dilutive $11MM loan, and has hired or his hiring 40 rps to cover 6K vet clinics. http[...]
Re: $CHMA Here's another one I just received: http://seekingalpha.com/article/3323855-chiasma-ipo-consider-a-small-allocation?isDirectRoadblock=false&uprof=51[...]
Re: $DNAI I just came across this artile on an upcoming oncology-related IPO. I've never heard of this company and I don't think I could add more to what Mr. Dion states in his article. Any thoughts from Dr. KSS and other experts in the matter? http://se[...]
Re: $CYNAD/$CTH/$CYNA Hi Franklyn. It appears to be so. http://www.nasdaq.com/symbol/cynad/press-releases[...]
Re: MERS Dr. KSS, I agree with what you wrote. However, how likely are pharma companies to seize upon this opportunity to lobby for more money for vaccine development, or stocking of medicines to combat the "coming epidemic." My point being that I'm not s[...]
Re: MERS US officials calling the country grossly unprepared for a MERS epidemic. Reminds me of the Ebola scare and the annual influenza onslaught which profits many pharmas. Any ideas on how to play this latest "scare", or indeed if there is a play at al[...]
$CYNACynapsus Therapeutics, presently trading on Toronto Stock Exchange under ticker CTH, is IPO’ing on 6/18. The company is a specialty CNS pharmaceutical company developing and preparing to commercialize a Phase 3, fast-acting, easy-to-use, subling[...]
$NVLS Nivalis Therapeutics (previously N30 Pharmaceuticals) is due to IPO on 6/17/15 at a price range between $13-$15. It is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for pa[...]
Hi Mark: No, there are myriad ways to get out of jury duty but I never have to use any of them. As soon as I say I was a litigator, I'm out. Unfortunately, sometimes you have to sit in the jury selection room for days before your number is called and the[...]
Re: $HALO-$ABBV Apologies for the tardy reply, I was on jury duty. While I would be indeed delighted to look up HALO's patents (a very easy task on USPTO.gov), I'm afraid that patent law is a very, very specialized area of the law. Pulling up the patents [...]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
$ESPR- $AMGN I would think this to be good (though limited) for ESPR: http://www.pmlive.com/pharma_news/smc_rejects_amgens_repatha_over_lack_of_outcomes_data_1041901?utm_medium=nl&utm_source=internal&mrkid=706415&mkt_tok=eyJpIjoiTWpJME1tWmtZak15TVRNMSIsI[...]